Pimavanserin
NUPLAZID
NADAC/unit
$170.4960
No Shortage
Tier 1: 35.9%
PA Req: 199.4%
NUPLAZID ® is indicated for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis [ see Clinical Studies (14) ] .
vs. brand NUPLAZID: Generic saves up to -1605% per unit
Generic Manufacturers
ACADIA PHARMACEUTICALS INC
Explore in the Ecosystem
Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.